CoChat
Sign Up
Cited by 341

The gut microbiome: an orchestrator of xenobiotic metabolism

Collins, Stephanie L., Patterson, Andrew D.·2020·Acta Pharmaceutica Sinica B
DOI 10.1016/j.apsb.2019.12.001PMC PMC6984741
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2019.12.001

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 117

  1. [3]Human Microbiome Project Consortium The human microbiome project consortium structure, function and diversity of the healthy human microbiome Nature 486 2012 207 214 22699609 PMC3564958
  2. [4]Abubucker S. Segata N. Goll J. Schubert A.M. Izard J. Cantarel B.L. Metabolic reconstruction for metagenomic data and its application to the human microbiome PLoS Comput Biol 8 2012 e1002358 PMC3374609 22719234
  3. [5]Hosokawa T. Kikuchi Y. Nikoh N. Shimada M. Fukatsu T. Strict host-symbiont cospeciation and reductive genome evolution in insect gut bacteria PLoS Biol 4 2006 e337 PMC1592312 17032065
  4. [6]Gibson G.R. Hutkins R. Sanders M.E. Prescott S.L. Reimer R.A. Salminen S.J. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics Nat Rev Gastroenterol Hepatol 14 2017 491 502 28611480
  5. [7]Canfora E.E. Jocken J.W. Blaak E.E. Short-chain fatty acids in control of body weight and insulin sensitivity Nat Rev Endocrinol 11 2015 577 591 26260141
  6. [9]Claesson M.J. Jeffery I.B. Conde S. Power S.E. O'Connor E.M. Cusack S. Gut microbiota composition correlates with diet and health in the elderly Nature 488 2012 178 184 22797518
  7. [10]Obermajer T. Grabnar I. Benedik E. Tušar T. Robič Pikel T. Fidler Mis N. Microbes in infant gut development: placing abundance within environmental, clinical and growth parameters Sci Rep 7 2017 11230 28894126 PMC5593852
  8. [11]Belkaid Y. Segre J.A. Dialogue between skin microbiota and immunity Science 346 2014 954 959 25414304
  9. [12]Gensollen T. Iyer S.S. Kasper D.L. Blumberg R.S. How colonization by microbiota in early life shapes the immune system Science 352 2016 539 544 27126036 PMC5050524
  10. [13]Sudo N. Chida Y. Aiba Y. Sonoda J. Oyama N. Yu X.N. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice J Physiol 558 2004 263 275 15133062 PMC1664925
  11. [14]Trompette A. Gollwitzer E.S. Yadava K. Sichelstiel A.K. Sprenger N. Ngom-Bru C. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis Nat Med 20 2014 159 166 24390308
  12. [15]Hsiao E.Y. McBride S.W. Hsien S. Sharon G. Hyde E.R. McCue T. The microbiota modulates gut physiology and behavioral abnormalities associated with autism Cell 155 2013 1451 1463 24315484 PMC3897394
  13. [17]Rastelli M. Knauf C. Cani P.D. Gut microbes and health: a focus on the mechanisms linking microbes, obesity, and related disorders Obesity 26 2018 792 800 29687645 PMC5947576
  14. [18]Nicholson J.K. Holmes E. Kinross J. Burcelin R. Gibson G. Jia W. Host–gut microbiota metabolic interactions Science 336 2012 1262 1267 22674330
  15. [21]Williams R.T. The metabolism of certain drugs and food chemicals in man Ann NY Acad Sci 179 1971 141 154 4998909
  16. [22]Selye H. Hormones and resistance J Pharm Sci 60 1971 1 28 4926765
  17. [23]Zimmermann M. Zimmermann-Kogadeeva M. Wegmann R. Goodman A.L. Mapping human microbiome drug metabolism by gut bacteria and their genes Nature 570 2019 462 467 31158845 PMC6597290
  18. [24]Nicholson J.K. Wilson I.D. Understanding “global” systems biology: metabonomics and the continuum of metabolism Nat Rev Drug Discov Lond 2 2003 668 676 12904817
  19. [25]Hayes C.L. Dong J. Galipeau H.J. Jury J. McCarville J. Huang X. Commensal microbiota induces colonic barrier structure and functions that contribute to homeostasis Sci Rep 8 2018 14184 30242285 PMC6155058
  20. [26]Koppel N. Maini Rekdal V. Balskus E.P. Chemical transformation of xenobiotics by the human gut microbiota Science 356 2017 eaag2770 PMC5534341 28642381
  21. [27]Strong H.A. Renwick A.G. George C.F. Liu Y.F. Hill M.J. The reduction of sulphinpyrazone and sulindac by intestinal bacteria Xenobiotica 17 1987 685 696 3630204
  22. [28]Nelson D.R. Cytochrome P450 diversity in the tree of life Biochim Biophys Acta 1866 2018 141 154 PMC5681887 28502748
  23. [29]Chankhamjon P. Javdan B. Lopez J. Hull R. Chatterjee S. Donia M.S. Systematic mapping of drug metabolism by the human gut microbiome BioRxiv 2019 Available from: 10.1101/538215 PMC8591631 32526207 · DOI
  24. [30]Erdmann E. Schoner W. Ouabain-receptor interactions in (Na++K+)-ATPase preparations Naunyn Schmiedebergs Arch Pharmacol 283 1974 335 356 4278432
  25. [31]Lindenbaum J. Rund D.G. Butler V.P. Tse-Eng D. Saha J.R. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy N Engl J Med 305 1981 789 794 7266632
  26. [32]Dobkin J.F. Saha J.R. Butler V.P. Neu H.C. Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora Science 220 1983 325 327 6836275
  27. [35]Rekdal V.M. Bess E.N. Bisanz J.E. Turnbaugh P.J. Balskus E.P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism Science 364 2019 eaau6323 PMC7745125 31196984
  28. [37]Geller L.T. Barzily-Rokni M. Danino T. Jonas O.H. Shental N. Nejman D. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine Science 357 2017 1156 1160 28912244 PMC5727343
  29. [39]Micozzi D. Carpi F.M. Pucciarelli S. Polzonetti V. Polidori P. Vilar S. Human cytidine deaminase: a biochemical characterization of its naturally occurring variants Int J Biol Macromol 63 2014 64 74 24183806 PMC3904506
  30. [40]Zimmermann M. Zimmermann-Kogadeeva M. Wegmann R. Goodman A.L. Separating host and microbiome contributions to drug pharmacokinetics and toxicity Science 363 2019 eaat9931 PMC6533120 30733391
  31. [41]Chu J. Vila-Farres X. Inoyama D. Ternei M. Cohen L.J. Gordon E.A. Discovery of MRSA-active antibiotics using primary sequence from the human microbiome Nat Chem Biol 12 2016 1004 1006 27748750 PMC5117632
  32. [43]Schröder H. Campbell D.E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man Clin Pharmacol Ther 13 1972 539 551 4402886
  33. [44]Paniker U. Levine N. Dapsone and sulfapyridine Dermatol Clin 19 2001 79 86 11155588
  34. [45]Chan R.P. Pope D.J. Gilbert A.P. Sacra P.J. Baron J.H. Lennard-Jones J.E. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide Dig Dis Sci 28 1983 609 615 6345112
  35. [46]Takeno S. Sakai T. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction Teratology 44 1991 209 214 1925980
  36. [47]Linwu S.W. Syu C.J. Chen Y.L. Wang A.H. Peng F.C. Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines Biochem Pharmacol 78 2009 96 103 19447228
  37. [48]Adlercreutz H. Hämäläinen E. Gorbach S. Goldin B. Dietary phyto-oestrogens and the menopause in Japan Lancet 339 1992 1233 1349965
  38. [49]Chang Y.C. Nair M.G. Metabolism of daidzein and genistein by intestinal bacteria J Nat Prod 58 1995 1892 1896 8691209
  39. [51]Wang X.L. Hur H.G. Lee J.H. Kim K.T. Kim S.I. Enantioselective synthesis of S-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium Appl Environ Microbiol 71 2005 214 219 15640190 PMC544246
  40. [52]Hwang C.S. Kwak H.S. Lim H.J. Lee S.H. Kang Y.S. Choe T.B. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration J Steroid Biochem Mol Biol 101 2006 246 253 16965913
  41. [53]Bolca S. Possemiers S. Herregat A. Huybrechts I. Heyerick A. De Vriese S. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women J Nutr 137 2007 2242 2246 17885005
  42. [54]Frankenfeld C.L. Atkinson C. Thomas W.K. Gonzalez A.P. Jokela T. Wähälä K.T. High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart Br J Nutr 94 2005 873 876 16351761
  43. [55]Pizzolato J.F. Saltz L.B. The camptothecins Lancet 361 2003 2235 2242 12842380
  44. [56]Smith N.F. Figg W.D. Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol In Vitro 20 2006 163 175 16271446
  45. [57]Guthrie L. Gupta S. Daily J. Kelly L. Human microbiome signatures of differential colorectal cancer drug metabolism Npj Biofilms Microbiomes 3 2017 27 29104759 PMC5665930
  46. [58]Wallace B.D. Wang H. Lane K.T. Scott J.E. Orans J. Koo J.S. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme Science 330 2010 831 835 21051639 PMC3110694
  47. [59]Boelsterli U.A. Redinbo M.R. Saitta K.S. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies Toxicol Sci 131 2013 654 667 23091168 PMC3551426
  48. [61]Tremaroli V. Bäckhed F. Functional interactions between the gut microbiota and host metabolism Nature 489 2012 242 249 22972297
  49. [62]Ulluwishewa D. Anderson R.C. McNabb W.C. Moughan P.J. Wells J.M. Roy N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components J Nutr 141 2011 769 776 21430248
  50. [64]Meslin J.C. Sacquet E. Effects of microflora on the dimensions of enterocyte microvilli in the rat Reprod Nutr Dev 24 1984 307 314 6729241
  51. [65]Kashyap P.C. Marcobal A. Ursell L.K. Larauche M. Duboc H. Earle K.A. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice Gastroenterology 144 2013 967 977 23380084 PMC3890323
  52. [69]Heneghan J.B. Influence of microbial flora on xylose absorption in rats and mice Am J Physiol-Leg Content 205 1963 417 420 14065888
  53. [71]Sabolić I. Breljak D. Škarica M. Herak-Kramberger C.M. Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs Biometals 23 2010 897 926 20549307
  54. [72]Breton J. Daniel C. Dewulf J. Pothion S. Froux N. Sauty M. Gut microbiota limits heavy metals burden caused by chronic oral exposure Toxicol Lett 222 2013 132 138 23916686
  55. [74]Semova I. Carten J.D. Stombaugh J. Mackey L.C. Knight R. Farber S.A. Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish Cell Host Microbe 12 2012 277 288 22980325 PMC3517662
  56. [75]Pierantozzi M. Pietroiusti A. Galante A. Sancesario G. Lunardi G. Fedele E. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients Ann Neurol 50 2001 686 687 11706979
  57. [76]Pierantozzi M. Pietroiusti A. Sancesario G. Lunardi G. Fedele E. Giacomini P. Reduced l-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients Neurol Sci 22 2001 89 91 11487216
  58. [77]Niehues M. Hensel A. In-vitro interaction of l-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability?. J Pharm Pharmacol 61 2009 1303 1307 19814861
  59. [78]El-Nezami H. Kankaanpaa P. Salminen S. Ahokas J. Ability of dairy strains of lactic acid bacteria to bind a common food carcinogen, aflatoxin B1 Food Chem Toxicol 36 1998 321 326 9651049
  60. [79]Halttunen T. Collado M.C. El-Nezami H. Meriluoto J. Salminen S. Combining strains of lactic acid bacteria may reduce their toxin and heavy metal removal efficiency from aqueous solution Lett Appl Microbiol 46 2008 160 165 18028332
  61. [80]El-Nezami H. Polychronaki N. Salminen S. Mykkänen H. Binding rather than metabolism may explain the interaction of two food-grade Lactobacillus strains with zearalenone and its derivative α´-zearalenol Appl Environ Microbiol 68 2002 3545 3549 12089040 PMC126820
  62. [81]Daisley B.A. Monachese M. Trinder M. Bisanz J.E. Chmiel J.A. Burton J.P. Immobilization of cadmium and lead by Lactobacillus rhamnosus GR-1 mitigates apical-to-basolateral heavy metal translocation in a Caco-2 model of the intestinal epithelium Gut Microb 10 2018 321 333 PMC6546314 30426826
  63. [82]Bisanz J.E. Enos M.K. Mwanga J.R. Changalucha J. Burton J.P. Gloor G.B. Randomized open-label pilot study of the influence of probiotics and the gut microbiome on toxic metal levels in Tanzanian pregnant women and school children MBio 5 2014 e01580–e14 PMC4196227 25293764
  64. [83]Morozzi G. Cenci G. Scardazza F. Pitzurra M. Cadmium uptake by growing cells of gram-positive and gram-negative bacteria Microbios 48 1986 27 35 3796301
  65. [84]Tripathi A. Debelius J. Brenner D.A. Karin M. Loomba R. Schnabl B. The gut–liver axis and the intersection with the microbiome Nat Rev Gastroenterol Hepatol 15 2018 397 411 29748586 PMC6319369
  66. [85]Wallace B.D. Redinbo M.R. Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective Drug Metab Rev 45 2013 79 100 23210723 PMC4878694
  67. [86]Zanger U.M. Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 138 2013 103 141 23333322
  68. [88]Lundin A. Bok C.M. Aronsson L. Björkholm B. Gustafsson J.Å. Pott S. Gut flora, Toll-like receptors and nuclear receptors: a tripartite communication that tunes innate immunity in large intestine Cell Microbiol 10 2008 1093 1103 18088401
  69. [89]Selwyn F.P. Cheng S.L. Bammler T.K. Prasad B. Vrana M. Klaassen C. Developmental regulation of drug-processing genes in livers of germ-free mice Toxicol Sci 147 2015 84 103 26032512 PMC4560037
  70. [90]Toda T. Saito N. Ikarashi N. Ito K. Yamamoto M. Ishige A. Intestinal flora induces the expression of Cyp3a in the mouse liver Xenobiotica 39 2009 323 334 19350455
  71. [91]Saegusa J. Kubota H. Sialadenitis in IQI/Jic mice: a new animal model of Sjögren’s syndrome J Vet Med Sci 59 1997 897 903 9362038
  72. [92]Claus S.P. Ellero S.L. Berger B. Krause L. Bruttin A. Molina J. Colonization-induced host–gut microbial metabolic interaction MBio 2 2011 e00271–e10 PMC3045766 21363910
  73. [93]Kindt A. Liebisch G. Clavel T. Haller D. Hörmannsperger G. Yoon H. The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice Nat Commun 9 2018 3760 30218046 PMC6138742
  74. [94]Selwyn F.P. Cui J.Y. Klaassen C.D. RNA-seq quantification of hepatic drug processing genes in germ-free mice Drug Metab Dispos 43 2015 1572 1580 25956306 PMC4576678
  75. [95]Michaels S. Wang M.Z. The revised human liver cytochrome P450 “pie”: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics Drug Metab Dispos 42 2014 1241 1251 24816681 PMC4109210
  76. [96]Wilkinson G.R. Drug metabolism and variability among patients in drug response N Engl J Med 352 2005 2211 2221 15917386
  77. [97]Guengerich F.P. Johnson W.W. Ueng Y.F. Yamazaki H. Shimada T. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer Environ Health Perspect 104 1996 557 562 8781383 PMC1469621
  78. [98]Ramsdell H.S. Parkinson A. Eddy A.C. Eaton D.L. Bioactivation of aflatoxin B1 by human liver microsomes: role of cytochrome P450 IIIA enzymes Toxicol Appl Pharmacol 108 1991 436 447 1902334
  79. [99]Cheng J. Ma X. Krausz K.W. Idle J.R. Gonzalez F.J. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity Drug Metab Dispos 37 2009 1611 1621 19460945 PMC2712435
  80. [100]Selwyn F.P. Cheng S.L. Klaassen C.D. Cui J.Y. Regulation of hepatic drug-metabolizing enzymes in germ-free mice by conventionalization and probiotics Drug Metab Dispos 44 2016 262 274 26586378 PMC4746487
  81. [101]Xie H.J. Broberg U. Griskevicius L. Lundgren S. Carlens S. Meurling L. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin Bone Marrow Transplant 31 2003 197 203 12621481
  82. [102]Pinto A.G. Wang Y.H. Chalasani N. Skaar T. Kolwankar D. Gorski J.C. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression Clin Pharmacol Ther 77 2005 178 188 15735612
  83. [103]Pichard L. Fabre I. Fabre G. Domergue J. Saint Aubert B. Mourad G. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes Drug Metab Dispos Biol Fate Chem 18 1990 595 606 1981707
  84. [104]Westphal J.F. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin Br J Clin Pharmacol 50 2000 285 295 11012550 PMC2015000
  85. [105]Anzenbacher P. Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics Cell Mol Life Sci 58 2001 737 747 11437235 PMC11337355
  86. [106]Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons Drug Metab Pharmacokinet 21 2006 257 276 16946553
  87. [107]González-Sarrías A. Azorín-Ortuño M. Yáñez-Gascón M.J. Tomás-Barberán F.A. García-Conesa M.T. Espín J.C. Dissimilar in vitro and in vivo effects of ellagic acid and its microbiota-derived metabolites, urolithins, on the cytochrome P450 1A1 J Agric Food Chem 57 2009 5623 5632 19469472
  88. [108]Wikoff W.R. Anfora A.T. Liu J. Schultz P.G. Lesley S.A. Peters E.C. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites Proc Natl Acad Sci U S A 106 2009 3698 3703 19234110 PMC2656143
  89. [109]Zamek-Gliszczynski M.J. Hoffmaster K.A. Nezasa K. Tallman M.N. Brouwer K.L.R. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites Eur J Pharm Sci 27 2006 447 486 16472997
  90. [110]Gamage N. Barnett A. Hempel N. Duggleby R.G. Windmill K.F. Martin J.L. Human sulfotransferases and their role in chemical metabolism Toxicol Sci Off J Soc Toxicol 90 2006 5 22 16322073
  91. [111]Clayton T.A. Baker D. Lindon J.C. Everett J.R. Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism Proc Natl Acad Sci U S A 106 2009 14728 14733 19667173 PMC2731842
  92. [113]Okuda H. Nishiyama T. Ogura K. Nagayama S. Ikeda K. Yamaguchi S. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs Drug Metab Dispos Biol Fate Chem 25 1997 270 273 9152608
  93. [114]Do K.N. Fink L.N. Jensen T.E. Gautier L. Parlesak A. TLR2 controls intestinal carcinogen detoxication by CYP1A1 PLoS One 7 2012 e32309 PMC3307708 22442665
  94. [115]Frank M. Hennenberg E.M. Eyking A. Rünzi M. Gerken G. Scott P. TLR signaling modulates side effects of anticancer therapy in the small intestine J Immunol 194 2015 1983 1995 25589072 PMC4338614
  95. [116]Dethlefsen L. Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation Proc Natl Acad Sci U S A 108 Suppl 1 2011 4554 4561 20847294 PMC3063582
  96. [117]Jernberg C. Löfmark S. Edlund C. Jansson J.K. Long-term impacts of antibiotic exposure on the human intestinal microbiota Microbiology 156 2010 3216 3223 20705661
  97. [118]Maier L. Pruteanu M. Kuhn M. Zeller G. Telzerow A. Anderson E.E. Extensive impact of non-antibiotic drugs on human gut bacteria Nature 555 2018 623 628 29555994 PMC6108420
  98. [119]Feng R. Shou J.W. Zhao Z.X. He C.Y. Ma C. Huang M. Transforming berberine into its intestine-absorbable form by the gut microbiota Sci Rep 5 2015 12155 26174047 PMC4502414
  99. [120]Tian Y. Cai J. Gui W. Nichols R.G. Koo I. Zhang J. Berberine directly affects the gut microbiota to promote intestinal farnesoid X receptor activation Drug Metab Dispos 47 2019 86 93 30409838 PMC6323626
  100. [122]Sun L. Xie C. Wang G. Wu Y. Wu Q. Wang X. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin Nat Med 24 2018 1919 30397356 PMC6479226
  101. [123]Zhang L. Nichols R.G. Correll J. Murray I.A. Tanaka N. Smith P.B. Persistent organic pollutants modify gut microbiota–host metabolic homeostasis in mice through aryl hydrocarbon receptor activation Environ Health Perspect 123 2015 679 688 25768209 PMC4492271
  102. [124]Ratnaike R.N. Acute and chronic arsenic toxicity Postgrad Med J 79 2003 391 396 12897217 PMC1742758
  103. [125]Lu K. Abo R.P. Schlieper K.A. Graffam M.E. Levine S. Wishnok J.S. Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: an integrated metagenomics and metabolomics analysis Environ Health Perspect 122 2014 284 291 24413286 PMC3948040
  104. [126]Rubin D.C.S.S. Alava P. Zekker I. Du Laing G. van de Wiele T. Arsenic thiolation and the role of sulfate-reducing bacteria from the human intestinal tract Environ Health Perspect 122 2014 817 822 24833621 PMC4123032
  105. [127]van de Wiele T. Gallawa C.M. Kubachk K.M. Creed J.T. Basta N. Dayton E.A. Arsenic metabolism by human gut microbiota upon in vitro digestion of contaminated soils Environ Health Perspect 118 2010 1004 1009 20603239 PMC2920899
  106. [128]Coryell M. McAlpine M. Pinkham N.V. McDermott T.R. Walk S.T. The gut microbiome is required for full protection against acute arsenic toxicity in mouse models Nat Commun 9 2018 5424 30575732 PMC6303300
  107. [129]Lu K. Cable P.H. Abo R.P. Ru H. Graffam M.E. Schlieper K.A. Gut microbiome perturbations induced by bacterial infection affect arsenic biotransformation Chem Res Toxicol 26 2013 1893 1903 24134150 PMC3974266
  108. [130]Lu K. Mahbub R. Cable P.H. Ru H. Parry N.M. Bodnar W.M. Gut microbiome phenotypes driven by host genetics affect arsenic metabolism Chem Res Toxicol 27 2014 172 174 24490651 PMC3997221
  109. [131]Kaplan J.L. Shi H.N. Walker W.A. The role of microbes in developmental immunologic programming Pediatr Res 69 2011 465 472 21364495
  110. [132]Wang M. Monaco M.H. Donovan S.M. Impact of early gut microbiota on immune and metabolic development and function Semin Fetal Neonatal Med 21 2016 380 387 27132110
  111. [133]Lehmann G.M. LaKind J.S. Davis M.H. Hines E.P. Marchitti S.A. Alcala C. Environmental chemicals in breast milk and formula: exposure and risk assessment implications Environ Health Perspect 126 2018 096001 PMC6375394 30187772
  112. [134]Iszatt N. Janssen S. Lenters V. Dahl C. Stigum H. Knight R. Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month Microbiome 7 2019 34 30813950 PMC6393990
  113. [135]Jin Y. Wu S. Zeng Z. Fu Z. Effects of environmental pollutants on gut microbiota Environ Pollut 222 2017 1 9 28086130
  114. [136]Sueyoshi T. Li L. Wang H. Moore R. Kodavanti P.R. Lehmler H.J. Flame retardant BDE-47 effectively activates nuclear receptor CAR in human primary hepatocytes Toxicol Sci 137 2014 292 302 24218150 PMC3908718
  115. [137]Pacyniak E.K. Cheng X. Cunningham M.L. Crofton K. Klaassen C.D. Guo G.L. The flame retardants, polybrominated diphenyl ethers, are pregnane X receptor activators Toxicol Sci 97 2007 94 102 17324954
  116. [138]Li C.Y. Lee S. Cade S. Kuo L.J. Schultz I.R. Bhatt D.K. Novel interactions between gut microbiome and host drug-processing genes modify the hepatic metabolism of the environmental chemicals polybrominated diphenyl ethers Drug Metab Dispos 45 2017 1197 1214 28864748 PMC5649562
  117. [139]Novak R. Ingram M. Clauson S. Das D. Delahanty A. Herland A. A robotic platform for fluidically-linked human body-on-chips experimentation BioRxiv 2019 Available from: 10.1101/569541 · DOI

Cited by

Sorted by citations

Authors
Collins, S. L., & Patterson, A. D.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2020-01
Volume
10
Issue
1
Pages
19-32
ISSN
2211-3835
DOI
10.1016/j.apsb.2019.12.001
PMC
PMC6984741
Cited by
341
References
18
Language
en
Licence
Funders
USA (ES028288)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review